There is no ketamine dosing room in Land O' Lakes. The treatment happens at 27724 Cashford Circle, Suite 102, Wesley Chapel, FL 33544. There is no ketamine dosing suite in Land O' Lakes at Ascend, and nothing here should be read as suggesting one exists. The preparation administered there is compounded and not FDA-approved, explained in full below. The psychiatric evaluation that decides whether ketamine is appropriate can be done by Florida telehealth from 34637, 34638 or 34639. Call (813) 670-3005 or book a consultation.
Why the timeline looks nothing like an antidepressant's
Standard antidepressants act on serotonin, norepinephrine or dopamine signaling, and the clinical effect builds over four to six weeks because the change they produce is gradual downstream adaptation. Ketamine works through a different mechanism entirely. It blocks NMDA receptors, which alters glutamate signaling and appears to prompt rapid changes in synaptic connectivity. That is the reason the effect, when there is one, shows up in hours or days rather than in months.
Two practical consequences follow, and both shape how the series is run. The first is that response is assessed early. There is no equivalent of waiting six weeks to see whether a dose was worth continuing, so symptom scores are recorded at every visit and a flat trend by the fourth session is a genuine finding rather than a sign of impatience. The second is that the effect is not durable on its own. A rapid antidepressant response can fade within days to weeks, which is why treatment is structured as a series rather than a single dose, and why what happens after the series matters as much as the series itself.
This is also the reason ketamine is discussed as an addition to a treatment plan rather than as a replacement for one. The mechanism that produces a fast response does not, by itself, address the sleep, alcohol, thyroid or trauma problems that often sit underneath a persistent depression. Those get assessed in the same evaluation, because leaving them in place tends to shorten whatever benefit the series produces.
What happens in the weeks after the series ends
The end of the induction series is a decision point rather than a discharge. You are seen again once it is complete, scores are compared against the baseline recorded at the evaluation, and one of three plans follows. A clear response leads to a maintenance interval set by how long the effect actually holds for you, which for some patients is four weeks and for others is several months, and for a meaningful number is not needed at all. A partial response leads to a conversation about what else should carry more of the load. No response ends the ketamine plan.
The weeks immediately after the series are also when relapse is most likely, so what fills them matters. Psychotherapy started or resumed during this window tends to be more productive than the same therapy attempted at the low point beforehand, because the capacity to engage with it is usually higher. Sleep, alcohol intake and any existing medication regimen are reviewed at the same visit for the same reason. You cannot drive yourself home after any session, including a later maintenance one, and that is confirmed at check-in every time rather than assumed from your last visit.
Coordinating with a prescriber you already have
A lot of Land O' Lakes patients already have a psychiatric or primary care prescriber in Pasco County, and the useful thing about staying inside the same county is that coordination is straightforward. Bring the record to your evaluation: which medications, at what doses, for how long, and what actually happened on each. Treatment-resistant depression generally means an inadequate response to two or more antidepressants taken at therapeutic doses for an adequate trial, and that determination is made from specifics rather than impressions.
Ketamine is assessed as one component of a broader treatment plan rather than as a replacement for one. If someone else manages your ongoing medication, say so during the consultation so that coordination happens deliberately. The clinician who assesses you is the clinician who doses you. Anna Stouffer, MS, PMHNP-BC, FNP-BC holds board certification in both psychiatric-mental health and family practice, which is why the cardiac and medication questions that decide candidacy are answered inside your psychiatric appointment instead of being routed to a separate office for clearance and returned weeks later. What treatment costs is discussed when we call you back rather than posted, because it depends on what the evaluation concludes.
What is administered, and its approval status
Ketamine is not FDA-approved to treat depression, PTSD, anxiety, OCD, or chronic pain. The preparation used at Ascend is compounded, which means a pharmacy assembles it rather than a manufacturer producing a finished reviewed product, and a compounded medication is not FDA-approved for any use at all. The agency has assessed it for neither safety, nor effectiveness, nor manufacturing quality. This is repeated during your evaluation in plain language, and it is named in the informed consent you sign before a first dose along with the risks and the alternatives.
Two things follow from that status. Nothing is mailed to your home and no supply is issued for you to take on your own; the agency has published warnings about compounded ketamine shipped out for unsupervised self-administration, and every dose here is prepared for in-clinic use and given on site. And because ketamine is a Schedule III controlled substance with real potential for misuse and dependence, dosing frequency is decided by the practice and revisited at each follow-up rather than continuing on an open-ended schedule. There is no nasal-spray option and no at-home option here, and no version of this in which a preparation that is not FDA-approved leaves the clinic with you.
The evidence carries a limit worth naming as well. Most published research used infusion administration rather than the subcutaneous route given here, so the findings apply by reasonable inference rather than directly. Whatever any individual trial reported, the compounded preparation used at Ascend is not FDA-approved.
The day of a session, and the day after
Budget about two hours in the clinic. Check-in and baseline vital signs take the first quarter hour. The medication is given as one small subcutaneous injection, so there is no line to place and nothing running for the duration. The active window lasts roughly forty to sixty minutes in a private room, in a recliner, with an eye mask and headphones if you want them. Observation continues afterward until you are cleared, usually another twenty to thirty minutes, and you leave with whoever is there to drive you home. Blood pressure, heart rate and your overall response are monitored throughout. The medication itself is compounded and not FDA-approved, and the monitoring built around it is what makes this a clinical procedure.
During the active window most patients describe a dissociative or dreamlike state: the body can feel distant, colors and sounds can shift slightly, time stops running at its usual speed, and some people describe floating. None of that is a warning sign and none of it lasts; a staff member stays in the room throughout. The side effects seen most often are nausea, light-headedness and a short-lived rise in pulse and blood pressure, with a headache or tiredness sometimes arriving later, and these have usually resolved by discharge.
The following day is normally unremarkable. When response does come, patients more often describe a gradual lifting of heaviness across the series than a single dramatic moment, and sleep frequently settles before mood does. Some patients notice nothing meaningful across a full induction series, which is a real and expected outcome for a minority and is discussed directly at follow-up rather than met with more appointments.
Reasons the evaluation says no
The consultation screens for a specific set of findings, each of which can make ketamine inappropriate: cardiovascular disease that is severe or not under control, hypertension that is not controlled, active psychosis or a documented history of a primary psychotic disorder, substance use disorders that are active or untreated, and pregnancy. Arrive with every medication you take written down, over-the-counter products included. Benzodiazepines come up in more of these conversations than anything else. Stimulants, a number of blood pressure medications and MAOIs are checked as well, while mood stabilizers call for tighter coordination rather than ruling anything out.
There is also a sequencing answer. Three situations usually produce a recommendation to do something else first: standard medication and therapy that were never given a genuine trial, an acute crisis that needs a different level of care, and a request for one session rather than a planned series. If you are in immediate danger, call or text 988. Beyond depression, every condition considered here is weighed one at a time and against a thinner evidence base than the depression work supports. That applies to PTSD, to severe anxiety that has resisted standard treatment, to OCD, to bipolar depression, and to a narrow set of chronic pain presentations, and nobody in any of those groups is treated as certain to respond.
What the research shows
In anxiety that has resisted standard treatment, symptom scores fell in proportion to dose in a controlled trial (Glue P, et al., Journal of Psychopharmacology, 2017). That literature exists, but it is younger and thinner than the depression literature and should be read that way. A placebo-controlled add-on trial in bipolar depression (Diazgranados N, et al., Archives of General Psychiatry, 2010) found a rapid antidepressant response when ketamine was added to an existing mood stabilizer. In chronic PTSD, six doses given across two weeks produced a larger fall in symptom severity than an active comparator (Feder A, et al., American Journal of Psychiatry, 2021). More recent work has not reproduced that finding, which is why PTSD is discussed here with more caution than depression is.
Those are group results from research settings and they are not forecasts for an individual. Individual responses vary, not everyone responds, and ketamine is not FDA-approved for any of these conditions regardless of what a given trial found.
Land O' Lakes questions
Is any part of this available in Land O' Lakes itself?
Not one operated by Ascend. There is no ketamine dosing suite in Land O' Lakes at Ascend. Every dose is given at the Wesley Chapel suite, 27724 Cashford Circle, Suite 102. The evaluation itself can be done by Florida telehealth from home, so the assessment, the medication review and the decision about whether ketamine is appropriate all happen before the first session is booked.
Can I really not drive myself home afterward?
Correct, and the rule does not flex on the day. Your ride is confirmed at check-in before any medication is given. Judgment and reaction time can still be affected after the obvious effects have faded, which is why the requirement is absolute rather than left to how you feel.
My prescriber is already in Pasco County. Does that help?
It usually does. Ketamine is evaluated as part of a broader plan rather than as a replacement for it, so an accurate record of what has already been tried makes the recommendation sharper. Mention your current prescriber during the consultation so coordination is arranged rather than assumed.
How many visits before I know whether it is working?
There is no dependable timetable, and anyone offering one is guessing. A change can register after two or three sessions, or not until late in the series, or not at all. Because scores are recorded around every visit rather than once at the end, the decision to carry on or stop rests on a measured trend instead of on an impression formed during a good or bad week.
Is this the same thing as the at-home ketamine services advertised online?
No, and the difference is supervision rather than the molecule. Those services mail a compounded oral or sublingual preparation for you to take with nobody present and no vital signs recorded. Ascend gives a monitored subcutaneous injection in a private room and does not mail medication under any circumstances.
Will insurance cover the sessions?
Usually not for the dosing sessions. Plans treat racemic ketamine inconsistently, benefits are most often out of network, and Ascend does not bill insurance for the sessions at all. The psychiatric consultation is a separate matter and may be partly covered under your in-network psychiatric benefit, depending on the plan. Our insurance and payment page sets out what can be verified in advance.
The nearest neighboring service-area page is Lutz. For the full walkthrough of how a dosing day is run, see the Wesley Chapel ketamine page, and for the service overview, ketamine therapy at Ascend.
References
- Glue P, Medlicott NJ, Harland S, et al. Ketamine's dose-related effects on anxiety symptoms in patients with treatment refractory anxiety disorders. Journal of Psychopharmacology. 2017;31(10):1302-1305.
- Diazgranados N, Ibrahim L, Brutsche NE, et al. A randomized add-on trial of an N-methyl-D-aspartate antagonist in treatment-resistant bipolar depression. Archives of General Psychiatry. 2010;67(8):793-802.
- Feder A, Costi S, Rutter SB, et al. A randomized controlled trial of repeated ketamine administration for chronic post-traumatic stress disorder. American Journal of Psychiatry. 2021;178(2):193-202.